In a time when government wrangling about drug prices is more than commonplace, news of a biosimilar for the mega-blockbuster Humira being approved took the backseat to many other things.
Most Wall Street strategists agree that the way to play the fourth quarter and next year is with large cap stocks that pay and consistently increase their dividends.
Despite recent market headwinds and volatility, there are strong underlying fundamentals among the large cap pharmaceuticals that are continuing to drive them forward.
The August 31 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has significantly decreased.
The top analyst upgrades, downgrades and initiations seen on Thursday morning include Apple, Callon Petroleum, Hewlett Packard Enterprise, Lululemon Athletica, Nike and Rio Tinto.
The August 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has significantly decreased.
Credit Suisse has run bullish and bearish scenarios for what the firm feels is a reasonable upside and downside for each of its large cap pharmaceutical stocks.
The July 29 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest was lower.
In a recent research note, the analysts at Jefferies made a big move by adding Ball Corp. to the firm's well-respected Franchise Picks list of stocks to buy.
A new Jefferies research report features the firm's top pharmaceutical stock picks in order of preference, and AbbVie stays in the top position.
AbbVie released a better-than-expected second-quarter earnings report before the markets opened on Friday.
Chris Lange Despite the fact that energy has tumbled 20% from the highs posted in June, Jefferies remains bullish on the natural gas arena, and with good reason.
Bristol-Myers Squibb released a better-than-expected second-quarter earnings report before the markets opened on Thursday.
The short interest data have been released for the July 15 settlement date. For the selected pharmaceutical stocks, short interest was mixed.
SunTrust Robinson Humphrey feels that the major pharmaceutical companies will outperform the rest of the year, and they cite new products, attractive dividends and solid performance as positives.
